We are analyzing https://link.springer.com/article/10.1007/s12094-018-02011-9.

Title:
The role of immunotherapy in small cell lung cancer | Clinical and Translational Oncology
Description:
Despite decades of research, prognosis for SCLC patients remains poor, and treatment options limited. SCLC is an immunogenic tumor with high somatic mutation rates due to tobacco exposure resulting in potential neo-antigens, the presence of suppressed immune responses, and occurrence of paraneoplastic disorders. The use of T cell immune-checkpoint inhibitors (anti-PD1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab, tremelimumab) have shown promising antitumor activity with the potential to prolong survival in SCLC patients. In fact, atezolizumab when combined with chemotherapy has achieved the milestone of being the first drug to improve survival in patients with newly diagnosed extensive-stage SCLC. Other immunotherapeutic approaches evaluated in clinical trials for SCLC include the use of cytokines, cancer vaccines, antiganglioside therapies, TLR9 inhibition, anti-Notch signaling, and anti-CD47. This review discusses the rationale and clinical evidence of immunotherapy in SCLC, the conflictive clinical results of novel immunotherapeutic agents and combinatorial therapies under evaluation in SCLC patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, article, pubmed, google, scholar, lung, cas, oncol, cell, small, smallcell, phase, patients, clin, sclc, central, study, immunotherapy, trial, chemotherapy, treatment, ann, extensivestage, therapy, randomized, clinical, nivolumab, ipilimumab, results, res, httpsdoiorgs, immune, suppl, firstline, iii, oncology, transl, combination, content, pembrolizumab, atezolizumab, access, cells, rudin, httpsdoiorgjco, thorac, expression, nat, rev, maintenance,

Topics {✒️}

dll3-targeted antibody-drug conjugate extensive-disease-small-cell lung cancer wild-type p53-specific cytotoxic wild-type p53-specific cd4 month download article/chapter cell immune-checkpoint inhibitors small-cell lung cancer small-cell lung carcinoma org/professionals/physician_gls/pdf/sclc chimeric anti-gd2 antibody lambert-eaton myasthenic syndrome 13-cis-retinoic acid modulation care chemo-radiotherapy conducted bec2/bacille calmette-guerin received honorary/consulting fees anti–pd-l1 atezolizumab class fucosyl-gm1 mab pd-l1 expression anti-gd2 antibody therapy recombinant interferon-gamma maintenance line platinum-based chemotherapy extensive-stage sclc anti-pd-l1 oncology meets immunology high-risk neuroblastoma cancer\immunotherapy access eating cancer cells innate immune checkpoint limited-stage sclc t-helper cells full article pdf related subjects blocking cd47 signaling p53 cancer vaccine antibody-dependent cytotoxicity natl cancer inst genome-wide exome cd62lhighcd251 cd41 regulatory privacy choices/manage cookies rudin cm comprehensive genomic profiles anti-ctla-4 recombinant interferon gamma interferon alpha-2a pd-l1 natural interferon alfa cancer immunotherapy targeting mol cancer ther cancer chemother pharmacol achieve cancer cure

Questions {❓}

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?
Treatment for small cell lung cancer, where are we now?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The role of immunotherapy in small cell lung cancer
         description:Despite decades of research, prognosis for SCLC patients remains poor, and treatment options limited. SCLC is an immunogenic tumor with high somatic mutation rates due to tobacco exposure resulting in potential neo-antigens, the presence of suppressed immune responses, and occurrence of paraneoplastic disorders. The use of T cell immune-checkpoint inhibitors (anti-PD1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab, tremelimumab) have shown promising antitumor activity with the potential to prolong survival in SCLC patients. In fact, atezolizumab when combined with chemotherapy has achieved the milestone of being the first drug to improve survival in patients with newly diagnosed extensive-stage SCLC. Other immunotherapeutic approaches evaluated in clinical trials for SCLC include the use of cytokines, cancer vaccines, antiganglioside therapies, TLR9 inhibition, anti-Notch signaling, and anti-CD47. This review discusses the rationale and clinical evidence of immunotherapy in SCLC, the conflictive clinical results of novel immunotherapeutic agents and combinatorial therapies under evaluation in SCLC patients.
         datePublished:2019-01-12T00:00:00Z
         dateModified:2019-01-12T00:00:00Z
         pageStart:961
         pageEnd:976
         sameAs:https://doi.org/10.1007/s12094-018-02011-9
         keywords:
            Lung cancer
            Immunotherapy
            Immune-checkpoint inhibitors
            Cancer vaccines
            PD-1
            PD-L1
            CTLA-4
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12094-018-02011-9/MediaObjects/12094_2018_2011_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12094-018-02011-9/MediaObjects/12094_2018_2011_Fig2_HTML.png
         isPartOf:
            name:Clinical and Translational Oncology
            issn:
               1699-3055
               1699-048X
            volumeNumber:21
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. Calles
               url:http://orcid.org/0000-0002-2547-1947
               affiliation:
                     name:Hospital General Universitario Gregorio Marañon
                     address:
                        name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                        type:PostalAddress
                     type:Organization
                     name:Instituto de Investigacion Sanitaria Gregorio Marañon
                     address:
                        name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:G. Aguado
               affiliation:
                     name:Hospital General Universitario Gregorio Marañon
                     address:
                        name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Sandoval
               affiliation:
                     name:Hospital General Universitario Gregorio Marañon
                     address:
                        name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Álvarez
               affiliation:
                     name:Hospital General Universitario Gregorio Marañon
                     address:
                        name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                        type:PostalAddress
                     type:Organization
                     name:Instituto de Investigacion Sanitaria Gregorio Marañon
                     address:
                        name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The role of immunotherapy in small cell lung cancer
      description:Despite decades of research, prognosis for SCLC patients remains poor, and treatment options limited. SCLC is an immunogenic tumor with high somatic mutation rates due to tobacco exposure resulting in potential neo-antigens, the presence of suppressed immune responses, and occurrence of paraneoplastic disorders. The use of T cell immune-checkpoint inhibitors (anti-PD1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab, tremelimumab) have shown promising antitumor activity with the potential to prolong survival in SCLC patients. In fact, atezolizumab when combined with chemotherapy has achieved the milestone of being the first drug to improve survival in patients with newly diagnosed extensive-stage SCLC. Other immunotherapeutic approaches evaluated in clinical trials for SCLC include the use of cytokines, cancer vaccines, antiganglioside therapies, TLR9 inhibition, anti-Notch signaling, and anti-CD47. This review discusses the rationale and clinical evidence of immunotherapy in SCLC, the conflictive clinical results of novel immunotherapeutic agents and combinatorial therapies under evaluation in SCLC patients.
      datePublished:2019-01-12T00:00:00Z
      dateModified:2019-01-12T00:00:00Z
      pageStart:961
      pageEnd:976
      sameAs:https://doi.org/10.1007/s12094-018-02011-9
      keywords:
         Lung cancer
         Immunotherapy
         Immune-checkpoint inhibitors
         Cancer vaccines
         PD-1
         PD-L1
         CTLA-4
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12094-018-02011-9/MediaObjects/12094_2018_2011_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12094-018-02011-9/MediaObjects/12094_2018_2011_Fig2_HTML.png
      isPartOf:
         name:Clinical and Translational Oncology
         issn:
            1699-3055
            1699-048X
         volumeNumber:21
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. Calles
            url:http://orcid.org/0000-0002-2547-1947
            affiliation:
                  name:Hospital General Universitario Gregorio Marañon
                  address:
                     name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                     type:PostalAddress
                  type:Organization
                  name:Instituto de Investigacion Sanitaria Gregorio Marañon
                  address:
                     name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:G. Aguado
            affiliation:
                  name:Hospital General Universitario Gregorio Marañon
                  address:
                     name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Sandoval
            affiliation:
                  name:Hospital General Universitario Gregorio Marañon
                  address:
                     name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Álvarez
            affiliation:
                  name:Hospital General Universitario Gregorio Marañon
                  address:
                     name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
                     type:PostalAddress
                  type:Organization
                  name:Instituto de Investigacion Sanitaria Gregorio Marañon
                  address:
                     name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical and Translational Oncology
      issn:
         1699-3055
         1699-048X
      volumeNumber:21
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hospital General Universitario Gregorio Marañon
      address:
         name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
         type:PostalAddress
      name:Instituto de Investigacion Sanitaria Gregorio Marañon
      address:
         name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
         type:PostalAddress
      name:Hospital General Universitario Gregorio Marañon
      address:
         name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
         type:PostalAddress
      name:Hospital General Universitario Gregorio Marañon
      address:
         name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
         type:PostalAddress
      name:Hospital General Universitario Gregorio Marañon
      address:
         name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
         type:PostalAddress
      name:Instituto de Investigacion Sanitaria Gregorio Marañon
      address:
         name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. Calles
      url:http://orcid.org/0000-0002-2547-1947
      affiliation:
            name:Hospital General Universitario Gregorio Marañon
            address:
               name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
               type:PostalAddress
            type:Organization
            name:Instituto de Investigacion Sanitaria Gregorio Marañon
            address:
               name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:G. Aguado
      affiliation:
            name:Hospital General Universitario Gregorio Marañon
            address:
               name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:C. Sandoval
      affiliation:
            name:Hospital General Universitario Gregorio Marañon
            address:
               name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:R. Álvarez
      affiliation:
            name:Hospital General Universitario Gregorio Marañon
            address:
               name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
               type:PostalAddress
            type:Organization
            name:Instituto de Investigacion Sanitaria Gregorio Marañon
            address:
               name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
      name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
      name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
      name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
      name:Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
      name:Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(352)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.12s.

LINK . SPRINGER . COM {}